Adjuvant ipilimumab improves recurrence-free survival in high-risk stage III melanoma

Bookmark and Share
Published: 2 Jun 2014
Views: 2326
Prof Alexander M. Eggermont, Erasmus University, Rotterdam, The Netherlands

At a press conference at ASCO 2014, Prof Eggermont talks about the initial efficacy and safety results from the EORTC 18071 phase III trial which looked at the use of ipilimumab versus placebo after complete resection of stage III melanoma.

Read the article for more.